Strong sequential and YoY revenue growth, combined with improving operating loss trajectory, suggests the company is approaching breakeven. The Smith+Nephew distribution agreement milestone payment expected this quarter provides a near-term catalyst. However, the stock's historical negative reaction to positive reports and growing debt load warrant caution. Monitor Q3 for continued revenue acceleration and cash burn rate.
Price Chart
Executive Summary
Nuo Therapeutics reported Q2 2026 revenue of ~$1.77M, up >150% YoY, and a net operating loss of ~$167K, improved by ~$280K sequentially. The company amended its loan agreement with an interim $675K funding and has $325K remaining available. Revenue growth is strong, but the company remains unprofitable with a growing stockholders' deficit, and the stock has historically not responded positively to similar reports.
Key Financial Metrics
Key Facts
- Q2 2026 total revenue of $1,768,986, up >150% YoY from $700,202
- Q2 2026 net operating loss of ~$167,000, improved ~$280,000 from Q1 2026
- Net loss of $277,601 in Q2 2026 vs $649,689 in Q2 2025
- Product revenues increased 38% sequentially vs Q1 2026
- Amended loan agreement with interim funding of $675,000; $325,000 remaining available under $2M commitments
- Cash balance of $449,325 as of June 30, 2026, down from $548,946 at Dec 31, 2025
- Stockholders' deficit grew to $1,535,314 from $956,559 at year-end 2025
- Reimbursement fee milestone achieved under Smith+Nephew distribution agreement; payment expected this quarter
Financial Impact
Revenue grew >150% YoY to ~$1.77M; net loss improved to ~$278K from ~$650K YoY; loan facility expanded to $2M with $675K drawn
Risk Factors
- Growing stockholders' deficit ($1.54M) and accumulated deficit ($35.67M) indicate ongoing capital needs
- Cash balance declining ($449K) despite loan draw; may require additional financing
- Dependence on Medicare reimbursement changes and Smith+Nephew partnership for growth
- Loan agreement with $325K remaining availability may not be sufficient if growth slows
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-028109 |
| Document: aurx20260816c_8k.htm | 0001437749-26-028109 |
| Document: 0001437749-26-028109-index-headers.html | 0001437749-26-028109 |
| Document: 0001437749-26-028109-index.html | 0001437749-26-028109 |
| Document: 0001437749-26-028109.txt | 0001437749-26-028109 |
| 8-K Data (Synthetic) | 0001437749-26-028109 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 8-K | $1.30 | awaiting T+20 | — | $1.30 (−0.00%) |
Aug 17, 2026 10w ago | 8-K | $1.00 $1.25 | ▲ +25.00% | ▲ +26.53% | $1.30 (+30.00%) |
May 14, 2026 23w ago | 8-K | $1.35 $0.9674 | ▼ −28.34% | ▼ −30.46% | $1.30 (−3.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers